{"id":405,"date":"2020-07-28T10:09:41","date_gmt":"2020-07-28T10:09:41","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=405"},"modified":"2020-07-28T10:09:41","modified_gmt":"2020-07-28T10:09:41","slug":"28-july-2020-remdesivir-associated-with-significantly-greater-recovery-and-62-reduced-odds-of-death","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/28-july-2020-remdesivir-associated-with-significantly-greater-recovery-and-62-reduced-odds-of-death\/","title":{"rendered":"(28 July 2020) Remdesivir- associated with significantly greater recovery and 62% reduced odds of death"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"wi-article-title article-title-main\">Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1093\/cid\/ciaa1041<\/p>\n<p class=\"\">NCT04292899\/GS-US-540-5773&nbsp; is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort).&nbsp; Inclusion criteria were similar between studies: patients had confirmed SARS-CoV-2 infection, were hospitalized, had oxygen saturation 94% or lower on room air or required supplemental oxygen, and had pulmonary infiltrates. The primary endpoint was the proportion of patients with recovery on day 14, dichotomized from a 7-point clinical status ordinal scale. A key secondary endpoint was mortality.&nbsp; After the inverse probability of treatment weighting procedure 312 and 818 patients were counted in the remdesivir- and non-remdesivir-cohorts, respectively. At day 14, 74.4% of patients in the remdesivir-cohort had recovered versus 59.0% in the non-remdesivir-cohort (adjusted odds ratio 2.03: 95% confidence interval 1.34-3.08, p&lt;0.001). At day 14, 7.6% of patients in the remdesivir-cohort had died versus 12.5% in the non-remdesivir-cohort (adjusted odds ratio 0.38, 95% confidence interval: 0.22-0.68, p=0.001). In this comparative analysis, by day 14, remdesivir was associated with significantly greater recovery and 62% reduced odds of death versus standard-of-care treatment in patients with severe COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care https:\/\/doi.org\/10.1093\/cid\/ciaa1041 NCT04292899\/GS-US-540-5773&nbsp; is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort).&nbsp; Inclusion criteria were similar between studies: patients had confirmed SARS-CoV-2 infection, were hospitalized,&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/28-july-2020-remdesivir-associated-with-significantly-greater-recovery-and-62-reduced-odds-of-death\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(28 July 2020) Remdesivir- associated with significantly greater recovery and 62% reduced odds of death&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,5],"tags":[25],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/405"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=405"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/405\/revisions"}],"predecessor-version":[{"id":406,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/405\/revisions\/406"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}